# Clinical Presentation and Molecular Characteristics of Kabuki Syndrome With Congenital Hyperinsulinism: A Retrospective Study

**Authors:** Mélanie Gaudillière, Thibaud Armand, Valérie Senée, Carine Villanueva, Marc Nicolino, Kevin Perge

PMC · DOI: 10.7759/cureus.101532 · Cureus · 2026-01-14

## TL;DR

This study explores the high rate of congenital hyperinsulinism in Kabuki syndrome patients and its genetic basis.

## Contribution

The study identifies a strong correlation between specific KMT2D gene variants and hypoglycaemia in Kabuki syndrome.

## Key findings

- 33% of Kabuki syndrome patients presented neonatal hypoglycaemia, with 28% having congenital hyperinsulinism.
- All hypoglycaemic patients had truncating variants in the C-terminal part of the KMT2D gene.
- Diazoxide monotherapy was effective in managing hyperinsulinism in most cases.

## Abstract

Introduction: Kabuki syndrome (KS) is a rare disease predisposing to congenital hyperinsulinism (CHI). The incidence of CHI in KS may be higher than considered in practice, and appropriate management of hypoglycemia would reduce long-term neurologic morbidity in these patients. Thus, the aims of our study were to estimate the occurrence rate of CHI-related hypoglycaemia in KS, to describe its evolution, and to identify potential genotype-phenotype correlations.

Methods: We conducted a single-centre retrospective study in patients with KS from 1999 to 2024.

Results: Among the 18 patients identified with KS included in the study, six (33%) presented neonatal hypoglycaemia, of whom five (28%) demonstrated CHI. Of these five, three had persistent CHI. Only the three patients with this condition required anti-hypoglycaemic drugs. They all responded well to diazoxide monotherapy, and one then needed the addition of octreotide. Genetically, all patients had heterozygous variants of the KMT2D gene except one, who had a heterozygous microdeletion of the same gene. Among these 17 variants, the majority were truncating variants (10/17, 59%) (three nonsense variants, six frameshift variants, and one splicing variant). Seven variants were missense variants (7/17, 41%). Among the six patients with hypoglycaemia, all had nonsense or frameshift variants in the C-terminal part of the KMT2D protein.

Conclusions: This study illustrates the importance of systematic screening for hypoglycaemia in patients with early diagnosis of KS. Conversely, newborns or infants with CHI should be considered and possibly tested for this etiological diagnosis.

## Linked entities

- **Genes:** KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085]
- **Chemicals:** diazoxide (PubChem CID 3019), octreotide (PubChem CID 448601)
- **Diseases:** Kabuki syndrome (MONDO:0016512), congenital hyperinsulinism (MONDO:0017182)

## Full-text entities

- **Genes:** KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085] {aka AAD10, ALR, BCAHH, CAGL114, KABUK1, KMS}
- **Diseases:** hypoglycemia (MESH:D007003), CHI (MESH:D044903), KS (MESH:C537705), neonatal hypoglycaemia (MESH:D007232)
- **Chemicals:** octreotide (MESH:D015282), diazoxide (MESH:D003981)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12904306/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12904306/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12904306/full.md

---
Source: https://tomesphere.com/paper/PMC12904306